4.6 Review

Hemophagocytic lymphohistiocytosis (HLH): A heterogeneous spectrum of cytokine-driven immune disorders

Journal

CYTOKINE & GROWTH FACTOR REVIEWS
Volume 26, Issue 3, Pages 263-280

Publisher

ELSEVIER SCI LTD
DOI: 10.1016/j.cytogfr.2014.10.001

Keywords

Hemophagocytic lymphohistiocytosis; Macrophage activation syndrome; Cytokine storm; Animal models; Therapy

Funding

  1. Agency for Innovation by Science and Technology (IWT)
  2. Regional Government of Flanders (GOA program)
  3. Fund for Scientific Research Flanders (FWO-Vlaanderen)
  4. Interuniversity Attraction Poles (TAP)
  5. IWT

Ask authors/readers for more resources

Hemophagocytic lymphohistiocytosis (HLH) comprises a group of life-threatening immune disorders classified into primary or secondary HLH. The former is caused by mutations in genes involved in granule-mediated cytotoxicity, the latter occurs in a context of infections, malignancies or autoimmune/autoinflammatory disorders. Both are characterized by systemic inflammation, severe cytokine storms and immune-mediated organ damage. Despite recent advances, the pathogenesis of HLH remains incompletely understood. Animal models resembling different subtypes of HLH are therefore of great value to study this disease and to uncover novel treatment strategies. In this review, all known animal models of HLH will be discussed, highlighting findings on cell types, cytokines and signaling pathways involved in disease pathogenesis and extrapolating therapeutic implications for the human situation. (C) 2014 Elsevier Ltd. All rights reserved.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available